Infiltration of lynch colorectal cancers by activated immune cells associates with early staging of the primary tumor and absence of lymph node metastases

Clinical Cancer Research

Volumn 18, Issue 5, 2012, Pages 1237-1245

  De Miranda, Noel F C C ^a   Goudkade, Danny ^a   Jordanova, Ekaterina S ^a   Tops, Carli M J ^a   Hes, Frederik J ^a   Vasen, Hans F A ^a   Van Wezel, Tom ^a   Morreau, Hans ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CD8 ANTIGEN; GRANZYME B; HLA ANTIGEN CLASS 1;

ANTIGEN DETECTION; ANTIGEN EXPRESSION; ARTICLE; CANCER GROWTH; CANCER IMMUNOLOGY; CANCER LOCALIZATION; CANCER STAGING; CD8+ T LYMPHOCYTE; CELLULAR DISTRIBUTION; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCOMPETENT CELL; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; LYMPHOCYTIC INFILTRATION; PHENOTYPE; PRIMARY TUMOR; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TISSUE CHARACTERIZATION;

CD8-POSITIVE T-LYMPHOCYTES; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; GRANZYMES; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOPHENOTYPING; LYMPHATIC METASTASIS; LYMPHOCYTES, TUMOR-INFILTRATING; NEOPLASM STAGING; PHENOTYPE; T-LYMPHOCYTE SUBSETS;

EID: 84857777465     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-1997     Document Type: Article

References (45)

1. Klein J, Sato A. The HLA system-first of two parts. N Engl J Med 2000;343:702-9.
2. Stevanovic S, Schild H. Quantitative aspects of T cell activation - peptide generation and editing by MHC class I molecule. Semin Immunol 1999;11:375-84. (Pubitemid 30047499)
3. Chang CC, Ferrone S. Immune selective pressure and HLA class I antigen defects in malignant lesions. Cancer Immunol Immunother 2007;56:227-36. (Pubitemid 44833096)
4. de Miranda NF, Nielsen M, Pereira D, van Puijenbroek M, Vasen HF, Hes FJ, et al. MUTYH-associated polyposis carcinomas frequently lose HLA class I expression - a common event amongst DNA-repair-deficient colorectal cancers. J Pathol 2009;219:69-76.
5. Dierssen JW, de MirandaNF, Ferrone S, van Puijenbroek M, Cornelisse CJ, Fleuren GJ, et al. HNPCC versus sporadic microsatellite-unstable colon cancers follow different routes toward loss of HLA class I expression. BMC Cancer 2007;7:33.
6. Dierssen JW, de Miranda NF, Mulder A, van Puijenbroek M, Verduyn W, Claas F, et al. High-resolution analysis of HLA class I alterations in colorectal cancer. BMC Cancer 2006;6:233.
7. Kloor M, Becker C, Benner A, Woerner SM, Gebert J, Ferrone S, et al. Immunoselective pressure and human leukocyte antigen class I antigen machinery defects in microsatellite unstable colorectal cancers. Cancer Res 2005;65:6418-24. (Pubitemid 40994430)
8. Kloor M, Michel S, von Knebel DM. Immune evasion of microsatellite unstable colorectal cancers. Int J Cancer 2010;127:1001-10.
9. Koopman LA, van der Slik AR, Giphart MJ, Fleuren GJ. Human leukocyte antigen class I gene mutations in cervical cancer. J Natl Cancer Inst 1999;91:1669-77. (Pubitemid 29479935)
10. Maleno I, CabreraCM, Cabrera T, Paco L, Lopez-Nevot MA, Collado A, et al. Distribution of HLA class I altered phenotypes in colorectal carcinomas: high frequency of HLA haplotype loss associated with loss of heterozygosity in chromosome region 6p21. Immunogenetics 2004;56:244-53. (Pubitemid 39119279)
11. Bicknell DC, Kaklamanis L, Hampson R, Bodmer WF, Karran P. Selection for beta(2)-microglobulin mutation in mismatch repairdefective colorectal carcinomas. Curr Biol 1996;6:1695-7. (Pubitemid 27050239)
12. Ferris RL, Whiteside TL, Ferrone S. Immune escape associated with functional defects in antigen-processing machinery in head and neck cancer. Clin Cancer Res 2006;12:3890-5. (Pubitemid 44078071)
13. Seliger B, Atkins D, Bock M, Ritz U, Ferrone S, Huber C, et al. Characterization of human lymphocyte antigen class I antigen-processing machinery defects in renal cell carcinoma lesions with special emphasis on transporter-associated with antigen-processing downregulation. Clin Cancer Res 2003;9:1721-7. (Pubitemid 36554596)
14. Kloor M, Michel S, Buckowitz B, Ruschoff J, Buttner R, Holinski-Feder E, et al. Beta2-microglobulin mutations in microsatellite unstable colorectal tumors. Int J Cancer 2007;121:454-8. (Pubitemid 46917717)
15. Campoli M, Chang CC, Ferrone S. HLA class I antigen loss, tumor immune escape and immune selection. Vaccine 2002;20:A40-5. (Pubitemid 35449404)
16. Khong HT, Restifo NP. Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol 2002;3:999-1005. (Pubitemid 35363649)
17. Speetjens FM, Lauwen MM, Franken KL, Janssen-van Rhijn CM, van DS, Bres SA, et al. Prediction of the immunogenic potential of frameshift-mutated antigens in microsatellite instable cancer. Int J Cancer 2008;123:838-45. (Pubitemid 352032410)
18. Schwitalle Y, Kloor M, Eiermann S, Linnebacher M, Kienle P, Knaebel HP, et al. Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers. Gastroenterology 2008;134:988-97. (Pubitemid 351459601)
19. Umar A, Risinger JI, Hawk ET, Barrett JC. Guidelines-testing guidelines for hereditary non-polyposis colorectal cancer. Nat Rev Cancer 2004;4:153-8. (Pubitemid 38198743)
20. Hendriks YM, de Jong AE, Morreau H, Tops CM, Vasen HF, Wijnen JT, et al. Diagnostic approach and management of Lynch syndrome (hereditary nonpolyposis colorectal carcinoma): a guide for clinicians. CA Cancer J Clin 2006;56:213-25. (Pubitemid 44175050)
21. Vasen HF, de Vos tot Nederveen Cappel WH. Cancer: Lynch syndrome - how should colorectal cancer be managed? Nat Rev Gastroenterol Hepatol 2011;8:184-6.
22. Sandel MH, Speetjens FM, Menon AG, Albertsson PA, Basse PH, Hokland M, et al. Natural killer cells infiltrating colorectal cancer and MHC class I expression. Mol Immunol 2005;42:541-6. (Pubitemid 39655966)
23. Menon AG, Janssen-van Rhijn CM, Morreau H, Putter H, Tollenaar RA, van de Velde CJ, et al. Immune system and prognosis in colorectal cancer: a detailed immunohistochemical analysis. Lab Invest 2004;84:493-501. (Pubitemid 41656477)
24. Bernal M, Concha A, Saenz-Lopez P, Rodriguez AI, Cabrera T, Garrido F, et al. Leukocyte infiltrate in gastrointestinal adenocarcinomas is strongly associated with tumor microsatellite instability but not with tumor immunogenicity. Cancer Immunol Immunother 2011;60:869-82.
25. Dolcetti R, Viel A, Doglioni C, Russo A, Guidoboni M, Capozzi E, et al. High prevalence of activated intraepithelial cytotoxic T lymphocytes and increased neoplastic cell apoptosis in colorectal carcinomas with microsatellite instability. Am J Pathol 1999;154:1805-13. (Pubitemid 29262862)
26. Smyrk TC, Watson P, Kaul K, Lynch HT. Tumor-infiltrating lymphocytes are a marker formicrosatellite instability in colorectal carcinoma. Cancer 2001;91:2417-22. (Pubitemid 32552830)
27. Umar A, Boland CR, Terdiman JP, Syngal S, de la Chapelle A, Ruschoff J, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 2004;96:261-8. (Pubitemid 38256271)
28. Sernee MF, Ploegh HL, Schust DJ. Why certain antibodies cross-react with HLA-A and HLA-G: Epitope mapping of two common MHCclass I reagents. Mol Immunol 1998;35:177-88. (Pubitemid 28319923)
29. Stam NJ, Spits H, Ploegh HL. Monoclonal antibodies raised against denatured HLA-B locus heavy chains permit biochemical characterization of certain HLA-C locus products. J Immunol 1986;137:2299-306. (Pubitemid 16020728)
30. Perosa F, Luccarelli G, Prete M, Favoino E, Ferrone S, Dammacco F. Beta 2-microglobulin-free HLA class I heavy chain epitope mimicry by monoclonal antibody HC-10-specific peptide. J Immunol 2003;171:1918-26. (Pubitemid 36966475)
31. Rivoltini L, Barracchini KC, Viggiano V, Kawakami Y, Smith A, Mixon A, et al. Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen-specific cytotoxic T lymphocytes. Cancer Res 1995;55:3149-57.
32. Gao FG, Khammanivong V, Liu WJ, Leggatt GR, Frazer IH, Fernando GJ. Antigen-specific CD4+T-cell help is required to activate a memory CD8+ T cell to a fully functional tumor killer cell. Cancer Res 2002;62:6438-41. (Pubitemid 35364102)
33. Zhang N, Bevan MJ. CD8(+) T cells: foot soldiers of the immune system. Immunity 2011;35:161-8.
34. Nouri-Shirazi M, Banchereau J, Bell D, Burkeholder S, Kraus ET, Davoust J, et al. Dendritic cells capture killed tumor cells and present their antigens to elicit tumor-specific immune responses. J Immunol 2000;165:3797-803. (Pubitemid 32057286)
35. Lovig T, Andersen SN, Thorstensen L, Diep CB, Meling GI, Lothe RA, et al. Strong HLA-DR expression in microsatellite stable carcinomas of the large bowel is associated with good prognosis. Br J Cancer 2002;87:756-62. (Pubitemid 35178753)
36. Michel S, Linnebacher M, Alcaniz J, Voss M, Wagner R, Dippold W, et al. Lack of HLA class II antigen expression in microsatellite unstable colorectal carcinomas is caused by mutations in HLA class II regulatory genes. Int J Cancer 2010;127:889-98.
37. Long EO, Burshtyn DN, Clark WP, Peruzzi M, Rajagopalan S, Rojo S, et al. Killer cell inhibitory receptors: diversity, specificity, and function. Immunol Rev 1997;155:135-44. (Pubitemid 27076065)
38. Karre K. Natural killer cells and the MHC class I pathway of peptide presentation. Semin Immunol 1993;5:127-45.
39. Carrega P, Pezzino G, Queirolo P, Bonaccorsi I, Falco M, Vita G, et al. Susceptibility of human melanoma cells to autologous natural killer (NK) cell killing: HLA-related effector mechanisms and role of unlicensed NK cells. PLoS One 2009;4:e8132.
40. Bernal M, Garrido P, Jimenez P, Carretero R, Almagro M, Lopez P, et al. Changes in activatory and inhibitory natural killer (NK) receptors may induce progression to multiple myeloma: implications for tumor evasion of T and NK cells. Hum Immunol 2009;70:854-7.
41. Ye SR, Yang H, Li K, Dong DD, Lin XM, Yie SM. Human leukocyte antigen G expression: as a significant prognostic indicator for patients with colorectal cancer. Mod Pathol 2007;20:375-83. (Pubitemid 46348337)
42. Drescher KM, Sharma P, Lynch HT. Current hypotheses on how microsatellite instability leads to enhanced survival of Lynch Syndrome patients. Clin Dev Immunol 2010;2010:170432
43. Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 2005;23:609-18. (Pubitemid 46224239)
44. Nosho K, Baba Y, Tanaka N, Shima K, Hayashi M, Meyerhardt JA, et al. Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review. J Pathol 2010;222:350-66.
45. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006;313:1960-4. (Pubitemid 44498003)